NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2025)
Historic EBT Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 20691.09%.
- NewAmsterdam Pharma's EBT Margin fell 206339000.0% to 20691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 627.28%, marking a year-over-year decrease of 352400.0%. This contributed to the annual value of 530.25% for FY2024, which is 7253200.0% up from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's EBT Margin is 20691.09%, which was down 206339000.0% from 90.7% recorded in Q2 2025.
- NewAmsterdam Pharma's EBT Margin's 5-year high stood at 57.19% during Q3 2024, with a 5-year trough of 20691.09% in Q3 2025.
- Moreover, its 3-year median value for EBT Margin was 1602.62% (2023), whereas its average is 3797.5%.
- As far as peak fluctuations go, NewAmsterdam Pharma's EBT Margin soared by 54386900bps in 2024, and later tumbled by -206339000bps in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's EBT Margin stood at 6160.4% in 2023, then surged by 88bps to 721.71% in 2024, then plummeted by -2767bps to 20691.09% in 2025.
- Its EBT Margin stands at 20691.09% for Q3 2025, versus 90.7% for Q2 2025 and 1327.3% for Q1 2025.